Intranasal Peptide Delivery: Pharmacokinetic Foundations

Intranasal delivery has emerged as a promising route for peptide administration, offering unique pharmacokinetic advantages over traditional subcutaneous and intramuscular routes. This article examines the pharmacokinetic foundations of intranasal peptide absorption.

Nasal Cavity Anatomy and Physiology

The nasal cavity provides a highly vascularized mucosal surface of approximately 150-160 cm² in adults. The rich vascular network beneath the epithelial layer enables rapid systemic absorption, while the relatively thin epithelial barrier (compared to gastrointestinal mucosa) facilitates peptide transit into the bloodstream.

Bypassing First-Pass Metabolism

One of the primary advantages of intranasal peptide delivery is the avoidance of hepatic first-pass metabolism. Orally administered peptides face near-complete degradation in the gastrointestinal tract and liver, with bioavailability often below 1%. Intranasal delivery routes peptides directly into the systemic circulation via the nasal vascular bed, preserving a greater fraction of the active compound.

The Nose-to-Brain Pathway

Perhaps the most scientifically significant aspect of intranasal delivery is the direct nose-to-brain pathway. Peptides absorbed through the olfactory epithelium can access the central nervous system via:

1. •Olfactory nerve pathway — transport along olfactory sensory neurons to the olfactory bulb
2. •Trigeminal nerve pathway — transport along trigeminal nerve fibers to brainstem regions

This pathway effectively bypasses the blood-brain barrier (BBB), which typically excludes most peptides from CNS access. Semax and Selank are examples of peptides developed specifically for intranasal administration to target CNS effects.

Bioavailability Considerations

Intranasal peptide bioavailability varies widely depending on:

• •Molecular weight — smaller peptides (<5 kDa) generally achieve better nasal absorption
• •Lipophilicity — more lipophilic peptides cross epithelial membranes more readily
• •Charge — the nasal epithelium has a net negative charge, favoring cationic peptides
• •Formulation — permeation enhancers, pH, and osmolarity significantly affect absorption

Limitations

Intranasal delivery has constraints: limited volume capacity (typically 25-200 μL per nostril), mucociliary clearance that removes administered compounds within 15-20 minutes, and potential for nasal irritation or mucosal damage with repeated administration.

Clinical Context

BPC-157 has been studied via multiple routes including intranasal administration, with preclinical evidence suggesting systemic bioavailability via the nasal route. However, rigorous pharmacokinetic studies comparing intranasal to subcutaneous bioavailability for most research peptides remain limited in the published literature.

Research Use Only. Not for human consumption. All referenced compounds are intended for laboratory research purposes only.